enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pertuzumab - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab

   Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...

3. Pertuzumab/trastuzumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab/trastuzumab/...

   The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...

4. FDA Grants Genentech's Perjeta Accelerated Approval for Use ...

   www.aol.com/news/2013-09-30-fda-grants-genen...

   FDA Grants Genentech's Perjeta Accelerated Approval for Use Before Surgery in People With HER2-Positive Early Stage Breast Cancer The Perjeta regimen is the first treatment approved under a new ...

5. Mepolizumab - Wikipedia

   en.wikipedia.org/wiki/Mepolizumab

   Phase III clinical trials in severe eosinophilic asthma were completed in 2014. The FDA approved it in November 2015. [14] The European Commission granted a marketing authorization valid throughout the European Union on 2 December 2015. [8] Mepolizumab was approved for medical use in the European Union in December 2015. [5]

6. FDA Advisory Committee Recommends Accelerated Approval of ...

   www.aol.com/news/2013-09-12-fda-advisory...

   FDA Advisory Committee Recommends Accelerated Approval of Genentech's Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer The FDA Will Make a Final Decision by October 31 The ...

7. FDA Grants Genentech's Perjeta Regimen Priority Review for ...

   www.aol.com/2013/07/02/fda-grants-genentechs...

   For premium support please call: 800-290-4726 more ways to reach us

8. Trastuzumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab/hyaluronidase

   [1] [2] It is a combination of trastuzumab and hyaluronidase. [ 1 ] [ 2 ] [ 3 ] The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction , upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity.

9. Roche's combo therapy for advanced breast cancer gets U.S ...

   www.aol.com/news/roches-combo-therapy-advanced...

   For premium support please call: 800-290-4726 more ways to reach us